The MRC/ABPI COPD Cohort v1.7 (COPDMAP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The UK Medical Research Council (MRC) together with the Association of British Pharmaceutical Industries (ABPI) have recently funded a program designed to foster collaboration between academic COPD researchers and the pharmaceutical industry in the UK, with the aim of developing and furthering our research capacity and expertise for the benefit of patients living with this prevalent and disabling condition. This builds on the strong international track record of COPD research in the UK. The program is divided into four work packages (WP1-4), each with specific aims. WP1 will collate and establish data from patient cohorts and share this information through the development of knowledge management platforms. WP2 will specifically assess how airway micro-organisms impact on COPD and how the effects of bacteria and viruses may be modified. WP3 is concerned with tissue injury and repair which are fundamental processes in the development of COPD. WP4 will examine in detail the potential for improving patient outcomes by targeting the skeletal muscle dysfunction that can profoundly affect exercise capacity.
| Condition | Intervention |
|---|---|
|
COPD |
Radiation: CT scan and PA chest X-ray |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Mechanisms of Inflammation and Immunity in COPD and Their Relationship to Exacerbations and Disease Progression. |
Blood, sputum and urine samples will be collected. Commercially available ELISA assays will be be used to qualify inflammatory markers.
Quantitative bacterial culture will be performed on sputum samples. Bacterial and viral load will be determined by polymerase chain reaction (PCR). Proteomics such as Cholesterol, BNP, CRP by routine hospital assay techniques. Specific DNA sections will be selected from the genome to identify/confirm genes believed to be associated with different COPD phenotypes by molecular techniques.
| Estimated Enrollment: | 400 |
| Study Start Date: | February 2011 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| COPD, GOLD II severity or above |
Radiation: CT scan and PA chest X-ray
All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated. The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK. |
Show Detailed Description Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients will be recruited from existing cohorts and may have participated in previously approved studies.
Potential primary care patients will be identified from databases held in practices and contacted, by the GP, by letter in the first instance. If the patient replies to the GP that they are willing to participate in the research, then a telephone call will be made by the research team to arrange a clinic visit.
Potential outpatient participants will be identified by the outpatient respiratory physician and if willing to participate will be referred to the research team via telephone call or referral letter.
Inclusion Criteria:
- Confirmed spirometric evidence of moderate to very severe COPD (stage II to IV) according to the WHO GOLD criteria:
- All patients FEV1/FVC <70%
- Stage II FEV1 50-80% predicted
- Stage III FEV1 30-50% predicted
- Stage IV FEV1 <30% predicetd or <50% predicted and chronic respiratory symptoms
- Past or present smokers
- Gender: male or female
- Age >40 years at recruitment
- Reasonable command of English to complete daily diary cards
Exclusion Criteria:
- History of asthma
- History of neoplasia
- History of other significant respiratory disease
- Pregnancy
Contacts and Locations| United Kingdom | |
| Royal Free Hampstead NHS Trust | Recruiting |
| London, United Kingdom, NW3 2QG | |
| Contact: Richa Singh, MA MBBS MRCP +442077940500 ext 34308 r.singh@ucl.ac.uk | |
| Contact: Gavin Donaldson, BSc PhD +442077940500 ext 34308 g.donaldson@ucl.ac.uk | |
| Principal Investigator: Wisia Wedzicha, BSc MBBS MD | |
More Information
No publications provided
| Responsible Party: | University College, London |
| ClinicalTrials.gov Identifier: | NCT01620645 History of Changes |
| Other Study ID Numbers: | CSP-83727 |
| Study First Received: | June 13, 2012 |
| Last Updated: | June 13, 2012 |
| Health Authority: | United Kingdom: Medical Research Council |
Additional relevant MeSH terms:
|
Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 16, 2013